疑诊体先型与脑先型帕金森病的18F-Florzolotau tau PET探索性研究
结果显示PDpRBD+组右侧楔前叶和左侧后扣带回摄取高于PDpRBD-组,且体先型患者右侧边缘及旁边缘结构摄取与MMSE评分呈负相关。提示两种假设亚型间tau PET信号存在差异。
要点
- 体先型帕金森病右侧楔前叶和左侧后扣带回18F-Florzolotau摄取高于脑先型。
- 体先型患者右侧边缘及旁边缘结构tau摄取与MMSE评分呈负相关。
- 研究为探索性初步结果,亚型相关tau PET差异尚需进一步验证。
核心结论
- 疑诊体先型与脑先型帕金森病之间18F-Florzolotau tau PET摄取模式存在差异。
- 体先型患者右侧边缘及旁边缘结构tau摄取与MMSE评分呈负相关。
研究设计与样本
- 所有受试者接受临床评估和18F-Florzolotau PET/CT成像。
主要发现
- PDpRBD+组右侧楔前叶和左侧后扣带回18F-Florzolotau摄取高于PDpRBD-组。
- 体先型帕金森病患者右侧边缘及旁边缘结构18F-Florzolotau摄取与MMSE评分呈负相关。
临床怎么用
- 18F-Florzolotau tau PET可能有助于在体区分帕金森病体先型与脑先型亚型。
- 对疑诊体先型患者,tau PET边缘及旁边缘结构信号或可提示认知功能相关改变。
局限性
- 本研究为探索性初步研究,样本量有限,结论尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The proposed body-first and brain-first Parkinson's disease (PD) subtypes are classified based on the initial localization of α-synuclein inclusions. Emerging evidence indicates the copathology of α-synuclein and tau in PD. However, the topographical pattern of tau deposition and its difference between these two phenotypes remain unclear. This study aimed to describe the tau deposits via 18F-Florzolotau PET/CT imaging in PD patients with the putative body-first and brain-first subtypes. METHODS: A total of ten PD patients with presumed body-first subtypes (PDpRBD+), sixteen PD patients with presumed brain-first subtypes (PDpRBD-), and seventeen healthy controls (HCs) were enrolled. Clinical assessments and 18F-Florzolotau PET imaging were conducted. RESULTS: 18F-Florzolotau uptake was higher in the right precuneus and left posterior cingulate regions in the PDpRBD+ group than in the PDpRBD- group. Additionally, 18F-Florzolotau uptake in the right limbic and paralimbic structures was inversely correlated with Mini-Mental State Examination (MMSE) scores in PD patients with the putative body-first subtype. CONCLUSION: Our preliminary findings demonstrated distinct 18F-Florzolotau uptake patterns between the hypothesized PD subtypes. These results provide in vivo evidence of subtype-related differences in tau PET signals, suggesting potential heterogeneity beyond classical α-synuclein pathology, though further validation is warranted.
引用
- Xu C, Jiao F, Ni Y, et al. An exploratory 18F-Florzolotau tau PET study in putative body-first versus brain-first Parkinson's disease. Eur J Nucl Med Mol Imaging. 2026. PMID: 42322399. doi:10.1007/s00259-026-08017-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。